Get the Stockscreener App
0.246
3.19%
-0.0081
IGC Pharma Inc stock is traded at $0.246, with a volume of 403.25K.
It is down -3.19% in the last 24 hours and down -9.56% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.2541
Open:
$0.26
24h Volume:
403.25K
Relative Volume:
0.56
Market Cap:
$25.43M
Revenue:
$1.20M
Net Income/Loss:
$-5.34M
P/E Ratio:
-4.7126
EPS:
-0.0522
Net Cash Flow:
$-6.27M
1W Performance:
-12.11%
1M Performance:
-9.56%
6M Performance:
-23.36%
1Y Performance:
-38.68%
1-Day Range:
$0.242
$0.26
1-Week Range:
$0.242
$0.285
52-Week Range:
$0.235
$0.4508
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.246 | 25.43M | 1.20M | -5.34M | -6.27M | -0.0522 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
IGC Pharma Inc Stock (IGC) Latest News
IGC Pharma (AMEX:IGC): What Changes After Its Latest Company Update? - Kalkine Media
IGC Pharma Unveils PRISM AI Platform for Alzheimer’s Care - ACCESS Newswire
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment - Eagle-Tribune
An AI tool aims to turn Alzheimer's risk predictions into ongoing brain-health tracking. - Stock Titan
IGC Pharma, Inc. (IGC) Launches PRISM AI to Commercialize Alzheimer’s Risk Tools - TradingView
4 Low-Priced Listed Stocks: VIVS, IGC, RIME, TOPP, With Catalysts to Watch - The Killeen Daily Herald
4 Low-Priced Listed Stocks: VIVS, IGC, RIME, TOPP, With Catalysts to Watch - FinancialContent
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 - ACCESS Newswire
2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus - FinancialContent
Press Releases about Ping An Biomedical Co., Ltd.Class A Ordinary Shares (Nasdaq:PASW) - FinancialContent
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 - BioBuzz
Each of two children received 100,000 shares as gifts from IGC Pharma (IGC) CEO Ram Mukunda. - Stock Titan
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50." - ACCESS Newswire
IGC Pharma Completes Enrollment in CALMA Phase 2 Trial for Alzhe - gurufocus.com
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 - BioSpace
168 people are enrolled in a trial for Alzheimer's-related agitation. Results are expected in 2026's final quarter. - Stock Titan
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 - The Globe and Mail
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - ACCESS Newswire
IGC Pharma Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
IGC Pharma Evaluates Recovery After Left Verdict - ACCESS Newswire
Price to earnings forward of IGC Pharma, Inc. – AMEX:IGC - TradingView
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer's 2027 Outlook - marketscreener.com
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer's 2027 Outlook - openPR.com
IGC Pharma (IGC) Slips to $0.31 as Key Support Comes into FocusIceberg Order - dars.gov.et
Nasdaq 30's VIVS, IGC, RIME, AIXI Stocks Now - openPR.com
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - FinancialContent
IGC (IGC) Technicals: Falls 0.65% to $0.31 on the Day; Level Watch: $0.29 and $0.33 Define the Nearby Reference Levels in the Latest ReadingLarge Cap Trends - vinanet.vn
MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now - openPR.com
IGC Pharma earnings matched, revenue fell short of estimates By Investing.com - Investing.com India
IGC (IGC) Earnings Data Review: The Bottom-Line Figure Outpaces Its Comparison at the Close; Session Reaction: Shares Move 1.43% Higher in the Current UpdatePost-Earnings Reaction - vinanet.vn
IGC Pharma earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
IGC Pharma earnings matched, revenue fell short of estimates - Investing.com
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - WBOC TV
IGC Pharma Releases Q2 2026 Financial Results - AlphaStreet
IGC Pharma execs buy 4.27M shares to settle $1.15M debt - scanx.trade
IGC Pharma Q2 Results: Sales up 39% YoY, EPS loss widens to $(0.03) - scanx.trade
IGC Looks 24.1% Overvalued on GF Value™ - GuruFocus
IGC Pharma Releases Q2 2026 Financial Results - AlphaStreet
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Finviz
IGC Pharma Q2 Results: CALMA Nears Enrollment Closure - accessnewswire.com
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - The Daily Corinthian
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Yahoo Finance
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Eagle-Tribune
IGC Pharma, Inc. 2026: Revenue $265K, EPS ($0.03) — 10-Q Summary - TradingView
IGC Pharma (NYSE: IGC) widens loss while Phase 2 Alzheimer’s trial hits key milestone - Stock Titan
IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build - openPR.com
Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build - FinancialContent
IGC Pharma (NYSE American:IGC): What Does the Latest Update Mean for Clinical Development? - Kalkine Media
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
IGC Pharma Inc Stock (IGC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mukunda Ram | CEO |
Apr 01 '26 |
Option Exercise |
0.13 |
656,410 |
84,000 |
4,649,088 |
| Mukunda Ram | CEO |
Apr 01 '26 |
Option Exercise |
0.00 |
49,999 |
0 |
910,751 |
| Moran James P | Director |
Apr 01 '26 |
Option Exercise |
0.00 |
130,000 |
0 |
1,235,735 |
| GRIMALDI CLAUDIA | PFO |
Apr 01 '26 |
Option Exercise |
0.15 |
238,462 |
36,000 |
1,372,714 |
| Mukunda Ram | CEO |
Feb 03 '26 |
Option Exercise |
0.00 |
50,000 |
0 |
860,752 |
| PRINS RICHARD K | Director |
Jan 19 '26 |
Option Exercise |
0.00 |
100,000 |
0 |
1,371,251 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):